R&G PharmaStudies Co., Ltd.

SZSE:301333 주식 보고서

시가총액: CN¥5.6b

R&G PharmaStudies 미래 성장

Future 기준 확인 4/6

R&G PharmaStudies is forecast to grow earnings and revenue by 27.8% and 18.8% per annum respectively. EPS is expected to grow by 23.8% per annum. Return on equity is forecast to be 10.5% in 3 years.

주요 정보

27.8%

수익 성장률

23.8%

EPS 성장률

Life Sciences 수익 성장34.7%
매출 성장률18.8%
향후 자기자본 수익률10.5%
애널리스트 커버리지

Low

마지막 업데이트05 Oct 2024

최근 미래 성장 업데이트

Recent updates

R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Jul 01
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Jun 06
Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Apr 29
Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

수익 및 매출 성장 예측

SZSE:301333 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261,149241N/A2482
12/31/2025986207N/A2124
12/31/2024812164N/A1523
9/30/2024759121152169N/A
6/30/2024738135194211N/A
3/31/2024738157177198N/A
12/31/2023721163173193N/A
9/30/2023694155175197N/A
6/30/2023673138106128N/A
3/31/2023628115126144N/A
1/1/2023638113110130N/A
9/30/2022634112121154N/A
6/30/202264011093127N/A
3/31/202263210166102N/A
1/1/20226089976115N/A
12/31/2020484841944N/A
12/31/20194258377103N/A
12/31/201514224N/A17N/A
12/31/20149614N/A24N/A
12/31/20137812N/A10N/A

애널리스트 미래 성장 예측

수입 대 저축률: 301333's forecast earnings growth (27.8% per year) is above the savings rate (2.9%).

수익 vs 시장: 301333's earnings (27.8% per year) are forecast to grow faster than the CN market (25.8% per year).

고성장 수익: 301333's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: 301333's revenue (18.8% per year) is forecast to grow faster than the CN market (14% per year).

고성장 수익: 301333's revenue (18.8% per year) is forecast to grow slower than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 301333's Return on Equity is forecast to be low in 3 years time (10.5%).


성장 기업 발견